Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
10 hedge funds and large institutions have $550K invested in Sonnet BioTherapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
367% more capital invested
Capital invested by funds: $118K → $550K (+$432K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
2.1% more ownership
Funds ownership: 0.26% → 2.36% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$459K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$402K |
| 3 |
VF
Virtu Financial
New York
|
+$36.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64.1K |
| 2 |
Citigroup
New York
|
-$71 |
| 3 |
Wells Fargo
San Francisco,
California
|
-$41 |
SONN Hedge Fund Activity: Q2 2024 in Review
10 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2024, worth a combined $550K — up 367% from $118K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SONN positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $459K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $64.1K sold.
- 10 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2024, up from 9 in Q1 2024.
- Funds reported $550K of Sonnet BioTherapeutics stock for Q2 2024, up 367% quarter-over-quarter.
- 4 funds opened new Sonnet BioTherapeutics positions in Q2 2024 and 3 closed out, a net change of +1 holder.
- The largest Sonnet BioTherapeutics buyer in Q2 2024 was Armistice Capital, an estimated $459K added.
- The largest Sonnet BioTherapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $64.1K sold.
Based on aggregated 13F filings for Q2 2024.